Symptomatic hyponatraemia associated with tolbutamide therapy

Area of Science:

• Endocrinology
• Pharmacology
• Nephrology

Background:

• Diabetes mellitus is a metabolic disorder requiring pharmacological management.
• Oral hypoglycemic agents, such as sulfonylureas, are commonly prescribed for type 2 diabetes.
• Tolbutamide and chlorpropamide are first-generation sulfonylureas with distinct pharmacokinetic profiles.

Observation:

• A case study details a patient with diabetes mellitus who developed hyponatraemic coma.
• The patient was undergoing treatment with tolbutamide for their diabetes.
• This clinical presentation occurred despite tolbutamide not being widely recognized for causing such severe water retention.

Findings:

• Hyponatraemic coma is a critical complication characterized by low sodium levels in the blood, leading to brain swelling.
• Tolbutamide, a sulfonylurea medication, was implicated in this specific case of hyponatraemic coma.
• The occurrence suggests a potential for tolbutamide to induce water retention, similar to but less commonly reported than with chlorpropamide.

Implications:

• This case underscores the importance of monitoring electrolyte balance in diabetic patients treated with sulfonylureas.
• Clinicians should be aware of the potential for hyponatraemic coma as a rare adverse effect of tolbutamide.
• Further research may be warranted to elucidate the mechanisms behind tolbutamide-induced water retention and hyponatremia.